Study to Evaluate 5-ALA Combined With CV01 Delivery of Ultrasound in Recurrent High Grade Glioma

Completed · Phase 1

Conditions studied: High Grade Glioma

In brief

A Phase 1 Multi-center clinical Trial Evaluating the Safety and Tolerability of 5-aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With recurrent High Grade Glioma (HGG).

Key facts

Study ID

NCT05362409

Run by

Alpheus Medical, Inc.

People needed

22

Starts

2022-06-29

Expected to finish

2025-02-03

Last updated by the study team

2025-06-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Washington University School of Medicine in St.Louis — St Louis, Missouri, United States
• Dent Neurosciences Research Center — Amherst, New York, United States
• Northwell — Lake Success, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.